109 related articles for article (PubMed ID: 11950909)
1. Markers of proliferative activity are predictors of patient outcome for low-grade endometrioid adenocarcinoma but not papillary serous carcinoma of endometrium.
Al Kushi A; Lim P; Aquino-Parsons C; Gilks CB
Mod Pathol; 2002 Apr; 15(4):365-71. PubMed ID: 11950909
[TBL] [Abstract][Full Text] [Related]
2. The frequency and significance of WT-1 expression in serous endometrial carcinoma.
Hedley C; Sriraksa R; Showeil R; Van Noorden S; El-Bahrawy M
Hum Pathol; 2014 Sep; 45(9):1879-84. PubMed ID: 25033726
[TBL] [Abstract][Full Text] [Related]
3. Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.
Brett MA; Atenafu EG; Singh N; Ghatage P; Clarke BA; Nelson GS; Bernardini MQ; Köbel M
Int J Gynecol Pathol; 2021 Mar; 40(2):116-123. PubMed ID: 32265358
[TBL] [Abstract][Full Text] [Related]
4. Correlation between immunohistochemical staining and clinicopathological findings in endometrial carcinoma.
Saharti SN; Altaf FJ
Saudi Med J; 2024 Jun; 45(6):560-564. PubMed ID: 38830650
[TBL] [Abstract][Full Text] [Related]
5. Correlative Assessment of p53 Immunostaining Patterns and TP53 Mutation Status by Next-Generation Sequencing in High-Grade Endometrial Carcinomas.
Matsumoto N; Manrai P; Rottmann D; Wu X; Assem H; Hui P; Buza N
Int J Gynecol Pathol; 2023 Nov; 42(6):567-575. PubMed ID: 36730675
[TBL] [Abstract][Full Text] [Related]
6. Prognostic importance of DNA ploidy and DNA index in stage I and II endometrioid adenocarcinoma of the endometrium.
Pradhan M; Abeler VM; Danielsen HE; Sandstad B; Tropé CG; Kristensen GB; Risberg BÅ
Ann Oncol; 2012 May; 23(5):1178-1184. PubMed ID: 21965471
[TBL] [Abstract][Full Text] [Related]
7. Distinct histological and clinical features associated with pure uterine serous carcinoma: A single institution experience.
Zhi W; Zhan Y; He C; Jin Y
Ann Diagn Pathol; 2023 Oct; 66():152173. PubMed ID: 37352704
[TBL] [Abstract][Full Text] [Related]
8. Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Hagemann IS; Deng W; Zaino RJ; Powell MA; Gunderson Jackson C; Cosgrove C; Mathews C; Pearl ML; Waggoner S; Ghebre R; Lele S; Guntupalli S; Secord AA; Ioffe O; Rasty G; Singh M; Soslow R; Creasman W; Mutch DG
Gynecol Oncol; 2023 Oct; 177():38-45. PubMed ID: 37634258
[TBL] [Abstract][Full Text] [Related]
9. Expressions of HuR, Methyl-HuR and Phospho-HuR in Endometrial Endometrioid Adenocarcinoma Are Associated with Clinical Features.
Hotton J; Gauchotte G; Mougel R; Migliorini M; Lacomme S; Battaglia-Hsu SF; Agopiantz M
Int J Mol Sci; 2024 Jan; 25(2):. PubMed ID: 38256026
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the localization of chondroitin sulfate in various types of endometrial carcinoma.
Hosokawa S; Norimatsu Y; Shinagawa A; Kurokawa T; Yoshida Y; Nishikawa T; Suzuki H; Irino S; Kobayashi TK
PLoS One; 2024; 19(5):e0304420. PubMed ID: 38805498
[TBL] [Abstract][Full Text] [Related]
11. Mesonephric-like Adenocarcinoma of the Uterine Corpus: Clinicopathological and Prognostic Significance of L1 Cell Adhesion Molecule (L1CAM) Over-expression.
Park S; Cho Y; Kim HS
Anticancer Res; 2023 Oct; 43(10):4559-4571. PubMed ID: 37772557
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Immunohistochemical Analysis of Mesonephric Marker Expression in Low-grade Endometrial Endometrioid Carcinoma.
Lee Y; Choi S; Kim HS
Int J Gynecol Pathol; 2024 May; 43(3):221-232. PubMed ID: 37566876
[TBL] [Abstract][Full Text] [Related]
13. Clinical Profile and Survival Outcome of Endometrial Cancer with p53 Mutation.
Tresa A; Sambasivan S; Rema P; Dinesh D; Sivaranjith J; Nair SP; Mathew A; Ammu JV; Kumar A
Indian J Surg Oncol; 2022 Sep; 13(3):580-586. PubMed ID: 36187514
[TBL] [Abstract][Full Text] [Related]
14. Gynecologic-Type Adenocarcinoma With Mixed Serous and Endometrioid Features in a Male Patient.
Gupta S; Schoolmeester JK; Erickson LA
Mayo Clin Proc; 2023 Aug; 98(8):1260-1262. PubMed ID: 37536812
[No Abstract] [Full Text] [Related]
15. Is HOXA5 a Novel Prognostic Biomarker for Uterine Corpus Endometrioid Adenocarcinoma?
Song C; Kim KB; Lee GS; Shin S; Kim B
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834206
[TBL] [Abstract][Full Text] [Related]
16. COX2 Effects on endometrial carcinomas progression.
Lyndin M; Kravtsova O; Sikora K; Lyndina Y; Kuzenko Y; Awuah WA; Abdul-Rahman T; Hyriavenko N; Sikora V; Romaniuk A
Pathol Res Pract; 2022 Oct; 238():154082. PubMed ID: 36049440
[TBL] [Abstract][Full Text] [Related]
17. Abnormal p53 expression is associated with poor outcomes in grade I or II, stage I, endometrioid carcinoma: a retrospective single-institute study.
Chang YW; Kuo HL; Chen TC; Chen J; Lim L; Wang KL; Chen JR
J Gynecol Oncol; 2024 Mar; ():. PubMed ID: 38576345
[TBL] [Abstract][Full Text] [Related]
18. Type II endometrial cancers: A case series.
Lobo FD; Thomas E
J Midlife Health; 2016; 7(2):69-72. PubMed ID: 27499593
[TBL] [Abstract][Full Text] [Related]
19. The prognostic value of P53 index in predicting the recurrence of early low-risk endometrial cancer.
Çakır İ; Gülseren V; Aköz G; Şahin Z; Sever B; Çakır ZE; Sancı M; Kuru O; Özdemir İA; Güngördük K
J Obstet Gynaecol Res; 2023 Oct; 49(10):2487-2493. PubMed ID: 37497887
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
